BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ismail IT, Elfert A, Helal M, Salama I, El-Said H, Fiehn O. Remodeling Lipids in the Transition from Chronic Liver Disease to Hepatocellular Carcinoma. Cancers (Basel) 2020;13:E88. [PMID: 33396945 DOI: 10.3390/cancers13010088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Nabi MM, Mamun MA, Islam A, Hasan MM, Waliullah ASM, Tamannaa Z, Sato T, Kahyo T, Setou M. Mass spectrometry in the lipid study of cancer. Expert Rev Proteomics 2021;18:201-19. [PMID: 33793353 DOI: 10.1080/14789450.2021.1912602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Haberl EM, Pohl R, Rein-Fischboeck L, Höring M, Krautbauer S, Liebisch G, Buechler C. Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice. Lipids Health Dis 2021;20:135. [PMID: 34629057 DOI: 10.1186/s12944-021-01567-w] [Reference Citation Analysis]
3 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. Int J Mol Sci 2021;22:6900. [PMID: 34199035 DOI: 10.3390/ijms22136900] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Nenu I, Stefanescu H, Procopet B, Sparchez Z, Minciuna I, Mocan T, Leucuta D, Morar C, Grigorescu M, Filip GA, Socaciu C. Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis. JCM 2022;11:1292. [DOI: 10.3390/jcm11051292] [Reference Citation Analysis]
6 Bouzas Muñoz A, Giménez-Bastida JA, Tejedor AG, Haros CM, Gómez de Cedrón M, Ramírez de Molina A, Laparra Llopis JM. Intestinal Intervention Strategy Targeting Myeloid Cells to Improve Hepatic Immunity during Hepatocarcinoma Development. Biomedicines 2021;9:1633. [PMID: 34829862 DOI: 10.3390/biomedicines9111633] [Reference Citation Analysis]
7 Cerbu B, Grigoras ML, Bratosin F, Bogdan I, Citu C, Bota AV, Timircan M, Bratu ML, Levai MC, Marincu I. Laboratory Profile of COVID-19 Patients with Hepatitis C-Related Liver Cirrhosis. J Clin Med 2022;11:652. [PMID: 35160114 DOI: 10.3390/jcm11030652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Su T, Qin XY, Dohmae N, Wei F, Furutani Y, Kojima S, Yu W. Inhibition of Ganglioside Synthesis Suppressed Liver Cancer Cell Proliferation through Targeting Kinetochore Metaphase Signaling. Metabolites 2021;11:167. [PMID: 33803928 DOI: 10.3390/metabo11030167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Wang Q, Tan Y, Jiang T, Wang X, Li Q, Li Y, Dong L, Liu X, Xu G. Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma. Cells 2022;11:1066. [PMID: 35406630 DOI: 10.3390/cells11071066] [Reference Citation Analysis]
10 Jena PK, Setayesh T, Sheng L, Di Lucente J, Jin LW, Wan YY. Intestinal Microbiota Remodeling Protects Mice from Western Diet-Induced Brain Inflammation and Cognitive Decline. Cells 2022;11:504. [PMID: 35159313 DOI: 10.3390/cells11030504] [Reference Citation Analysis]
11 Monroe JD, Fraher D, Huang X, Mellett NA, Meikle PJ, Sinclair AJ, Lirette ST, Maihle NJ, Gong Z, Gibert Y. Identification of novel lipid biomarkers in xmrk- and Myc-induced models of hepatocellular carcinoma in zebrafish. Cancer Metab 2022;10:7. [PMID: 35379333 DOI: 10.1186/s40170-022-00283-y] [Reference Citation Analysis]